Cargando…
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
Metaphase cytogenetics (MC) has a major role in the risk stratification of patients with myelodysplastic syndromes (MDSs) and can affect the choice of therapies. Azacitidine (AZA) has changed the outcome of patients with MDS or acute myeloid leukemia (AML) unfit for intensive chemotherapy. Identific...
Autores principales: | Cluzeau, T, Moreilhon, C, Mounier, N, Karsenti, J-M, Gastaud, L, Garnier, G, Re, D, Montagne, N, Gutnecht, J, Auberger, P, Fuzibet, J G, Cassuto, J-P, Raynaud, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880435/ https://www.ncbi.nlm.nih.gov/pubmed/24185502 http://dx.doi.org/10.1038/bcj.2013.52 |
Ejemplares similares
-
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012) -
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
por: Cluzeau, Thomas, et al.
Publicado: (2014) -
Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020) -
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021) -
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)